Background: High plasma lipoprotein (a)[Lp (a)] level is a strong and important risk factor for
cardiovascular disease (CVD). Small-sized apolipoprotein (a)[apo (a)] isoforms (F, B, S1 …

Background—Serum lipoprotein (a)[Lp (a)] concentration is largely determined by variability
at the apolipoprotein (a) gene locus. Most prominent effects relate to polymorphisms in the …

Lipoprotein (a)[Lp (a)] is commonly referred to as a novel risk factor, but this is only partially
correct. Lp (a) was first described in 1963 by Berg and recognized as associated with …

Background Lipoprotein (a) concentrations in plasma are associated with cardiovascular
risk in the general population. Whether lipoprotein (a) concentrations or LPA genetic …

Plasma lipoprotein (a)(Lp [a]) level is an independent risk factor of cardiovascular disease
that is under strong genetic control. We conducted a genome-wide association study of …

Abstract Lipoprotein (a)[Lp (a)] is a quantitative genetic trait in human plasma associated
with atherothrombotic disease. The major determinant of Lp (a) concentration is the …

Since the discovery of lipoprotein (a)[Lp (a)] by Kåre Berg in 1963, epidemiological and
genetic studies have consistently identified elevated Lp (a) as an independent causal risk …

Abstract Lipoprotein (a)[Lp (a)] is an atherogenic lipoprotein with a strong genetic regulation.
Up to 90% of the concentrations are explained by a single gene, the LPA gene. The …

Background There is a well-documented empirical relationship between lipoprotein (a)[Lp
(a)] and cardiovascular disease (CVD); however, causal evidence, especially from the …

Abstract Lipoprotein (a)[Lp (a)] concentrations are regulated by the LPA gene mainly via the
large kringle IV-type 2 (KIV-2) copy number variation and multiple causal variants. Early …